Medicenna Therapeutics Corp. (MDNA.TO)
Medicenna Therapeutics Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.40, down 0.00% on the session, giving a market capitalisation of $31.0M. Its beta of 1.89 implies it has historically moved more than the broad market.
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cytokine, has successfully finished Phase IIb trials for recurrent glioblastoma and is also being investigated for other brain and non-brain tumor types in earlier developmental stages. The company's pipeline also includes MDNA11, an improved IL-2 variant designed to stimulate immune responses against cancer; MDNA209, an IL-2 antagonist aimed at autoimmune conditions like multiple sclerosis and graft-versus-host disease; MDNA413, a dual IL-4/IL-13 antagonist for use in cancer immunotherapy; and MDNA132, an IL-13 Superkine targeting solid tumors. Furthermore, Medicenna utilizes its BiSKITs platform to engineer bespoke Superkines by joining them with proteins, antibodies, cytokines, or other Superkines. The company's main office is located in Toronto, Canada.
Medicenna Therapeutics Corp. is most often compared with the following Healthcare names: